Pulmonx to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
Rhea-AI Summary
Pulmonx Corporation (NASDAQ: LUNG), a leader in minimally invasive lung disease treatments, has announced its participation in the Goldman Sachs 46th Annual Global Health Care Conference. The presentation is scheduled for June 11, 2025, at 7:00 AM PT / 10:00 AM ET in Miami. Investors and interested parties can access both the live and archived webcast of the presentation through the company's investor relations website at investors.pulmonx.com.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, LUNG gained 8.11%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
REDWOOD CITY, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the company will be presenting at the Goldman Sachs 46th Annual Global Health Care Conference in Miami on Wednesday, June 11, 2025, at 7:00 AM PT / 10:00 AM ET.
A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTrax™ Platform, and StratX® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Pulmonx®, AeriSeal®, Chartis®, StratX®, and Zephyr® are registered trademarks and LungTraX™ is a trademark of Pulmonx Corporation.
Investor Contact
Jeremy Feffer
LifeSci Advisors
jfeffer@lifesciadvisors.com
FAQ
When is Pulmonx (LUNG) presenting at the Goldman Sachs Healthcare Conference 2025?
How can I watch Pulmonx's (LUNG) presentation at the Goldman Sachs Conference?
What does Pulmonx Corporation (LUNG) specialize in?
Where is the Goldman Sachs Healthcare Conference 2025 being held?
